Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA Rejects J & J Anesthesia System

By Drug Discovery Trends Editor | April 21, 2010

Health products maker Johnson & Johnson disclosed that the Food And Drug Administration has rejected a computer-assisted anesthesia system it developed that coincidentally uses propofol, the powerful anesthetic blamed in singer Michael Jackson’s overdose death.

Louise Mehrotra, head of investor relations, noted the decision during a company conference call with analysts Tuesday after J&J released its first-quarter results. She told analysts J&J has appealed, asking the FDA commissioner’s office for an administrative review by an independent advisory committee.

The FDA advisory panel previously recommended approval of the system.

The FDA, criticized in recent years amid drug safety problems, has become more cautious in its decisions, frequently demanding additional data or completely new studies before it will approve new products.

J&J did not announce the decision in a press release, as it generally does.

J&J spokeswoman Kelly Leadem told The Associated Press Tuesday that the FDA during the first quarter sent the company a “Not Approvable” letter and provided information on options New Brunswick, N.J.-based J&J could consider. Those options include doing additional clinical studies. She would not disclose the other options.

J&J had heavily touted its Sedasys system as the first one using a computer to monitor both anesthesia doses and patient vital signs during low-risk diagnostic procedures such as colonoscopies. It’s meant to be used by doctor-nurse teams during such procedures – where an anesthesiologist usually is not involved, Leadem said. She said the FDA has not yet responded to the appeal request.

The product, developed by J&J’s Ethicon Endo-Surgery business, is approved in the European Union for use during colonoscopies and screenings of the upper gastrointestinal tract and also is approved in Canada for use during routine colonoscopy, Leadem said.

Date: April 20, 2010
Source: Associated Press

 


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE